
    
      This study was to evaluate DRBP108 in the treatment of type 2 diabetes mellitus. A total of
      268 subjects were randomly allocated to four treatment arms: 50 mg, 100 mg, 200 mg or placebo
      group, in a 1:1:1:1 ratio.
    
  